David Callanan

SVP & Chief Medical Officer at Aviceda Therapeutics

Dr. Callanan has over 30 years of experience in Ophthalmology research & development. After receiving his MD at the University of Iowa College of Medicine, he accepted an Internal Medicine residency and ophthalmology residency at Parkland Memorial Hospital UT-Southwestern. He was a Heed Ophthalmic Foundation Fellow at the prestigious Eye Institute in US, Bascom Palmer Eye Institute in Miami, Florida. He completed fellowships in Medical Retina with legendary Dr. J. Donald M. Gass and Vtreoretinal surgery with the Bascom Palmer faculty. He also received additional training in uveitis with Dr. Robert Nussenblatt at the National Eye Institute in Bethesda, Maryland. Dr. Callanan joined Texas Retina Associates in 1993 and was appointed to the faculty at the University of Texas Southwestern Medical School the same year.

A respected leader in his field, Dr. Callanan has actively conducted clinical research throughout his career and has played an instrumental role in many ophthalmic global drug approvals including Lucentis and Eylea, and Ozurdex. He received a National Research Service Award from the National Eye Institute in 1985. His areas of focus include Vitreoretinal Surgery, Medical Retina, and Uveitis. He is passionate about improving care for patients with retina conditions and diseases, and he led global retina clinical trials focused on potential new treatments for macular edema, age-related macular degeneration (AMD), retinal vein occlusion and uveitis.

Dr. Callanan is a clinical professor in the Department of Ophthalmology at UT Southwestern Medical Center and also serves on the board of directors of the Retina Foundation of the Southwest. A member of numerous medical societies, including the American Academy of Ophthalmology, The Association for Research in Vision and Ophthalmology, The Macula Society, The American Uveitis Society, and the American Society of Retina Specialists, among others.

Links


Org chart